Evaluation of teriparatide for treatment of osteoporosis in four patients with cystic fibrosis: a case series.

• Type of Material: Article
• Authors: Oranan Siwamogsatham, Samitivej Srinakarin Hospital; Kelly Stephens, Emory University; Vin Tangpricha, Emory University
• Language: English
• Date: 2014
• Publisher: Hindawi Publishing Corporation
• Publication Version: Final Published Version
• Copyright Statement: © 2014 Oranan Siwamogsatham et al.
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.1155/2014/893589
• Title of Journal or Parent Work: Case Reports in Endocrinology
• ISSN: 2090-6501
• Volume: 2014
• Start Page: 893589
• End Page: 893589
• Keywords: Endocrinology & Metabolism
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Pharmacology

Abstract

Introduction: Bone disease is a common complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of teriparatide, recombinant human parathyroid hormone, to treat CF-related bone disease. Case Presentation: We report on four patients with CF-related bone disease who were treated with teriparatide. Three patients completed two years of therapy with teriparatide, and all had significant improvements in their bone mineral density (BMD). One patient was unable to tolerate teriparatide and discontinued treatment 1 week into therapy. Conclusion: Teriparatide may be a potential treatment option for CF-related bone disease. This report highlights the need for further investigation into the use of teripartide in the CF population.